SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules.Â
Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.
Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals
Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.
Home â–¸ Investors â–¸ Corporate Governance â–¸ Committees to the Board
The Board, on October 19, 2011, constituted the Audit and Risk Committee. At its meeting held on January 22, 2019, the Board has constituted an independent Risk Management Committee. Therefore, the Audit and Risk Committee was renamed as Audit Committee. The Audit Committee comprises three Independent Directors.
Ms. Sharmila Abhay Karve, Chairperson, Independent Director
Ms. Vinita Bali, Independent Director
Mr. Nilanjan Roy, Independent Director
The Nomination and Remuneration Committee reviews, acts on and reports to the Board with respect to various governance, nomination, compensation and performance evaluation matters. The Committee works with full autonomy and is free of any managerial interference.
Committee comprises the following board members:
Ms. Vinita Bali,  Chairperson,  Independent Director    Â
Dr. Vijay Kuchroo, Independent Director  Â
Prof. Catherine Rosenberg, Non-Executive Director
Ms. Sharmila Karve, Independent Director  Â
In terms of Section 135 of the Companies Act, 2013, the Board has constituted the Corporate social responsibility (CSR) Committee. The Committee comprises two Independent Directors and one Non-Executive Director
Prof. Catherine Rosenberg, Chairperson, Non-Executive Director
Ms. Vinita Bali, Independent Director
Dr Vijay Kuchroo, Independent Director
The Stakeholders Relationship Committee comprises three Independent Directors, one Non-Executive Director and one Executive Director
Ms. Sharmila Abhay Karve, Chairperson, Independent Director
Prof. Catherine Rosenberg, Non-Executive Director
Mr. Jonathan Hunt, Executive Director
Mr. Nilanjan Roy, Independent Director
Ms. Manja Boerman, Independent Director
The Board, on January 22, 2019, constituted the Risk Manangement Committee in accordance with Regulation 21 of the SEBI Listing Regulations.
The Risk Management Committee comprises three Independent Directors, and one Executive Director
Mr. Nilanjan Roy, Chairman, Independent Director
Mr. Jonathan Hunt, Â Executive Director
Dr. Kush Parmar, Independent Director
Ms. Manja Boerman, Independent Director
The Board, on October 21, 2021, constituted the Science and Technology Committee.
The Science and Technology Committee comprises three Independent Directors, one Non-Executive Director and one Executive Director
Dr. Vijay Kuchroo, Chairman, Independent Director
Prof. Catherine Rosenberg, Non- Executive Director
Dr. Kush Parmar, Independent Director
Mr. Jonathan Hunt, Executive Director
Ms. Manja Boerman, Independent Director
© 2023. Syngene International Limited